A Study to See if Memantine Protects the Brain during Radiation Therapy Treatment for Primary Central Nervous System Tumors

This phase III trial compares memantine to usual treatment in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.

Disease Sites:

Neuro-Oncology, Pediatrics

Staging:

Phase III

Age Group:

Children

Therapies:

Therapy (NOS)

Drugs:

Memantine, Placebo

Principal Investigator(s):

Esbenshade, Adam

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

09-13-2022

Trial Type:

Treatment

Protocol ID:

COGACCL2031

National Clinical Trial ID:

NCT04939597

Eligibility

Ages Eligible for Study:

4 Years

Genders Eligible for Study:

BOTH

Accepts Healthy Volunteers?:

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Study to See if Memantine Protects the Brain during Radiation Therapy Treatment for Primary Central Nervous System Tumors

Eligibility